ADC Manufacturing And The Challenges To Overcome
Source: Single Use Support
By Brian Moloney, Director New Products & Innovation

Antibody drug conjugates (ADCs) are a promising alternative for cancer therapy, but their high toxicity presents a lot of challenges. Companies working to scale up and industrial production of ADCs face complications due to the high safety measures needed to guarantee product efficacy and protect the working environment for staff and manufacturers.
This formulation is inspiring further research due to the potential it shows using mAbs in combination with a highly toxic payload drug to easily target cancer cells without potential harm to healthy cells.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Single Use Support
This website uses cookies to ensure you get the best experience on our website. Learn more